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Abstract
Glioma is the most malignant type of primary central nervous system tumors, and has an
extremely poor prognosis. One potential therapeutic approach is to induce the terminal dif-
ferentiation of glioma through the forced expression of pro-neural factors. Our goal is to
show the proof of concept of the neuronal conversion of C6 glioma through the combined
action of small molecules. We investigated the various changes in gene expression, cell-
specific marker expression, signaling pathways, physiological characteristics, and morphol-
ogy in glioma after combination treatment with two small molecules (CHIR99021, a glyco-
gen synthase kinase 3 [GSK3] inhibitor and forskolin, a cyclic adenosine monophosphate
[cAMP] activator). Here, we show that the combined action of CHIR99021 and forskolin con-
verted malignant glioma into fully differentiated neurons with no malignant characteristics;
inhibited the proliferation of malignant glioma; and significantly down-regulated gene ontol-
ogy and gene expression profiles related to cell division, gliogenesis, and angiogenesis in
small molecule–induced neurons. In vivo, the combined action of CHIR99021 and forskolin
markedly delayed neurological deficits and significantly reduced the tumor volume. We sug-
gest that reprogramming technology may be a potential treatment strategy replacing the
therapeutic paradigm of traditional treatment of malignant glioma, and a combination mole-
cule comprising a GSK3 inhibitor and a cAMP inducer could be the next generation of anti-
cancer drugs.
Introduction
It has been reported that mouse fibroblasts can be directly reprogrammed into neurons
through the forced expression of three pro-neuronal transcription factors (Brn2, Ascl1, and
Myt1l) [1]. Indeed, cell reprogramming techniques have progressed rapidly and are breaking
new ground in the field of regenerative medicine [2–9]. Glioma is the most malignant type of
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primary tumors, and has an extremely poor prognosis [10,11]. The direct conversion from
malignant to benign cells through the forced expression of pro-neural factors is a potent thera-
peutic strategy for removing tumor cells because terminally differentiated-cells will die from
apoptosis [12,13].
However, limitations in gene transfection efficiency for multiple-gene reprogramming
techniques have led researchers to investigate strategies that replace or decrease the number of
necessary reprogramming factors [14]. To this end, it was recently reported that somatic cells
can be converted into neurons through the forced expression of a single key factor, such as
Ascl1 or Neurod1 [15,16]. Despite this progress, intrinsic limitations related to chromosomal
gene insertion persist. Further, it was recently reported that mouse and human fibroblasts could
be converted into neurons using a small molecule cocktail of 4–7 molecules in vitro [17,18].
We observed the development of neuron-like cells in a glioma culture following the addi-
tion of a small-molecule mixture containing the GSK3 inhibitor CHIR99021 and the cAMP
activator forskolin, without forced-gene expression. Here, we investigated the various changes
relating to both neural differentiation and growth suppression after neural conversion, as well
as the signaling pathways involved in glioma–neural conversion by CHIR99021 and forskolin.
Further, we investigated whether direct reprogramming technology based on the combination
of small molecules can be applied to the treatment of malignant glioma. This study is the first
to show that glioma can be converted to neurons using small molecules without neural tran-
scription factors.
Materials and methods
Direct reprogramming of glioma to neurons using small molecules
Rat C6 glioma cells were cultured in DMEM (Invitrogen) containing 10% FBS (Hyclone) and
1% P/S (Invitrogen). C6 glioma cells have been tested previously [19]. Glioblastoma (GBM)
was established from patients as approved by the institutional review board of Severance Hos-
pital, Yonsei University College of Medicine [20]. GBM was cultured in DMEM/F12 (Corn-
ing) containing 2% B27, 1% P/S (Invitrogen), epidermal growth factor (EGF; 10 ng/ml) and
fibroblast growth factor 2 (FGF2; 10 ng/ml). For neuronal induction, C6 glioma was plated at
a density of 2 × 103 cells/cm2 on a matrigel (BD Bioscience)-coated 12-mm glass coverslip.
GBM were plated at density of 4 × 104 cells/cm2 on a matrigel (BD Bioscience)-coated 12-mm
glass coverslip. The following day, media were replaced with neural induction media consist-
ing of DMEM/F12 (Invitrogen): neurobasal medium (Invitrogen) (1:1 mixture) containing 1%
N2 (Invitrogen) and 2% B27 (Invitrogen) supplement, 1× Glutamax (Invitrogen), 0.05%
bovine serum albumin (BSA), β-mercaptoethanol, 1% P/S (Invitrogen), brain-derived neuro-
trophic factor (BDNF; 10 ng/mL, Peprotech), and glial cell-derived neurotrophic factor
(GDNF; 10 ng/mL, Peprotech). Two small molecules (CHIR99021 and forskolin) were added
into the neural induction media. The medium was replaced every 2~3 days.
In some experiments, mouse embryonic fibroblasts (MEFs) were used instead of glioma.
MEFs were seeded at a density of 1 × 104 cells/cm2 on a matrigel-coated 12-mm glass coverslip.
The following day, neural induction was performed, as described above.
Cell proliferation and toxicity assay
C6 glioma and GBM were cultured in culture medium containing dimethyl sulfoxide
(DMSO), CHIR99021 (2-20 μM), forskolin (10-100 μM), or a combination of CHIR99021 and
forskolin. On the day of the experiment, the medium was replaced with culture medium con-
taining 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma)
at a final concentration of 0.5 mg/mL, and incubated for 3 hours. Violet crystal was dissolved in
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DMSO and added to the wells. Absorbance was measured using an enzyme-linked immunosor-
bent assay (ELISA) plate reader (VERSAmax) at 490 nm. To test the cell toxicity, the number of
viable cells was counted by trypan blue staining after DMSO or small-molecule treatment.
Immunocytochemistry
Cells were washed with phosphate-buffered saline (PBS) and then fixed in 4% paraformalde-
hyde (Merck) for 10 minutes. Cells were then washed with PBS three times for 3 minutes per
wash, and subsequently incubated with a blocking solution (10% normal donkey serum, Jack-
son ImmunoResearch) for 1 hour at room temperature (RT). Cells were incubated with pri-
mary antibodies for 1 hour at RT, washed three times with PBS, incubated with secondary
antibody for 30 minutes at RT, and finally washed three more times and mounted with a
mounting solution (Vector Laboratories). Cells were analyzed using an Olympus BX51 fluo-
rescence microscope (Olympus) and an LSM 700 confocal microscope (ZEISS). The primary
antibodies used in this study were: Tuj1 (1:2000, Abcam), MAP2 (1:500, Abcam), Nestin
(1:1000, Millipore), GFAP (1:1000, Abcam), NG2 (1:200, Millipore), Olig2 (1:200, Abcam),
platelet-derived growth factor receptor (PDGFR; 1:500, Santa Cruz) and Ki67 (1:250, Abcam).
Whole-cell patch clamp
A cover slip with cultured cells was transferred to a recording chamber (Warner Instruments)
and placed under a microscope (Olympus). Artificial CSF, containing 124 mM NaCl, 3 mM
KCl, 1.3 mM MgSO4, 1.25 mM NaH2PO4, 26 mM NaHCO3, 2.4 mM CaCl2-2H2O, and 10
mM glucose (Sigma-Aldrich) was continuously perfused over the cells and aerated with O2
95%/CO2 5% mixed gas at RT. A glass capillary pipette was directed towards the cell surface.
Negative pressure was provided to elicit a gigaseal for whole-cell recording. The internal
pipette solution contained 115 mM K-gluconate, 10 mM KCl, 10 mM HEPES, 10 mM EGTA,
5 mM Mg-ATP, and 0.5 mM Na2+-GTP (Sigma-Aldrich), with pH 7.3 and 280–285 mOsm.
Sodium current was recorded in voltage clamp mode, and electrical stimulation was provided
in the range −60 mV to +20 mV. Thereafter, current clamp mode was utilized to evaluate
action potential generation. To verify that inward currents and spikes were mediated by volt-
age gated sodium channels, the bath was treated with tetrodotoxin (TTX; 0.5 μM, Sigma-
Aldrich) prior to recording. Data acquisition was performed using Digitizer 1440A (Molecular
Devices) and Clampex 10.3 (Molecular Devices). Analysis of data was conducted by using
Clampfit 10.3 (Molecular Devices).
DNA microarray analysis
Microarray analysis was performed according to the manufacturer’s instructions. After total
RNA isolation, cDNA was synthesized using the GeneChip WT (Whole Transcript) Amplifi-
cation kit. Labeled DNA target was hybridized to the Affymetrix GeneChip Array. Hybridized
arrays were washed and stained on a GeneChip Fluidics Station 450 and scanned on a
GCS3000 Scanner. Analysis was performed using Affymetrix1 GeneChip Command Con-
sole1 Software (AGCC). Microarray data have been deposited in a public database (https://
www.ncbi.nlm.nih.gov/geo/, GSE98656).
Intramedullary spinal cord tumor (IMSCT) model and small molecule
administration
Adult male C57BL mice (6 weeks, Orient Bio) were used for the IMSCT model. Zoletil 50 (30
mg/kg, Virbac) and Rompun (10 mg/kg, Bayer) were used for anesthesia. To establish the
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IMSCT, laminectomy was performed at the 10th thoracic level. For in vivo tracing, we used the
red fluorescent protein (RFP)-expressing C6 glioma [19]. Total 1 × 105 cells of RFP-express-
ing C6 glioma were injected at a rate of 1 μl/min. Two days after inoculation, animals were
divided into two groups: Group 1, water; Group 2, CHIR99021 (12.5 mg/kg, intraperitone-
ally) and forskolin (10 mg/kg, orally) once a day. To test neurological function, we observed
hind limb movements based on Basso Mouse Scale (BMS) score every day following the gli-
oma transplant.
In vivo imaging system (IVIS)
The IVIS Spectrum (Xenogen, Alameda, CA, USA) was used to measure a cell mass of RFP-
expressing C6 glioma. Sixteen days after glioma transplantation, the spinal cord was dissected,
and bioluminescence detection was conducted for 1 minute. Regions of interest (ROIs) were
analyzed, and total quantification of bioluminescence was performed using Living Image1
(Xenogen) software.
Western blot
On the day of the experiment, equal amounts of protein sample were loaded on an 8-10%
sodium dodecyl sulfate (SDS) gel and separated using SDS polyacrylamide gel electrophoresis
(SDS-PAGE). Then, the protein samples were transferred to a polyvinylidene difluoride
(PVDF) membrane for 1–2 hours at 100 V. After a blocking step with PBS containing 3% BSA,
the transferred membrane was incubated with primary antibody. The following day, the mem-
brane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1
hour, and then the detection procedure was performed. Primary antibodies were: stage-spe-
cific embryonic antigen 1 (SSEA-1; 1:1000, Invitrogen), actin (1:10000, Abcam), and C-Myc
(1:500, Santacruz).
Statistical analysis
Student’s t-test was performed to assess differences between two groups. Two-way analysis of
variance (ANOVA) was performed to assess differences among three groups or more. Data are
presented as the mean ± standard error of the mean (SEM) and p-values less than 0.05 were
considered to be statistically significant.
Study approval
All experiments were performed according to international guidelines on the ethical use of
animals, and the number of animals used was minimized. All protocols were approved by the
Yonsei University Health System Institutional Animal Care and Use Committee (YUHS-IA-
CUC). The patient provided written consent for their sample to be used in this study.
Results
The flexible neuronal conversion of malignant C6 glioma through the
action of small molecules
In this study, we determined that malignant glioma cells can be converted into fully differenti-
ated neurons through the combined action of two small molecules (CHIR99021, a GSK3
inhibitor, and forskolin, a cAMP activator) in the absence of neural transcription factors. The
typical morphology of a C6 glioma is shown in Fig 1A. The majority of C6 glioma cells strongly
expressed nestin and oligodendrocyte precursor cell markers such as PDGFR-α, NG-2, and
Olig2, but not the neuron-specific marker Tuj1 (Fig 1B). Seven days after treatment with
Neuronal direct conversion of glioma
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CHIR99021 or forskolin, Tuj1-positive cells were noted on C6 glioma, although the observed
conversion efficiency was low (Fig 1C). In contrast, we confirmed that fibroblasts could not be
converted into Tuj1-positive neurons by small molecule combination or single treatment (Fig
1D). Combined CHIR99021 and forskolin showed high efficiency conversion from glioma to
Tuj1-positive cells (Fig 1C). We thus selected the combination of CHIR99021 and forskolin
for further investigation. Seven days after the treatment with 20 μM CHIR99021 and 100 μM
forskolin, we observed a marked increase in the conversion efficiency of malignant C6 glioma
to Tuj1-positive cells (Fig 1E).
Direct reprogramming of C6 glioma to neurons using two small
molecules
Thirty-five days after neural induction with CHIR99021 and forskolin, most of the glioma was
converted into Tuj1-positive (~90%) or MAP2-positive (~80%) cells showing morphological
diversity (Fig 2A–2D). Some cells (~10%) had differentiated into GFAP-positive cells. How-
ever, cells expressing glioma markers PDGFR or NG2 were rarely observed 35 days after
small-molecule treatment (Fig 2A and 2B). We compared the protein expression pattern of
oncogene and cancer stem cell markers in C6 glioma and small molecule-induced neurons
(SMiNs). The expression level of SSEA1 (a cancer stem cell marker) and C-Myc (an oncogene
marker) was lower in SMiN compared with C6 glioma (Fig 2E). This result indicates that the
combination treatment of CHIR99021 and forskolin changed the tumor characteristics. In
addition, we investigated whether another GSK3 inhibitor (lithium carbonate) and cAMP acti-
vator (dbcAMP) induced neural conversion in malignant glioma. We found that the combina-
tion of lithium carbonate/forskolin or CHIR99021/dbcAMP was able to induce the neural
conversion of glioma (Fig 2F and 2G). These results suggest that a malignant glioma can be
converted into post-mitotic neurons through the application of a GSK3 inhibitor and a cAMP
Fig 1. The flexible neuronal conversion of malignant C6 glioma through the action of small
molecules. (A and B) Representative images of C6 glioma before neural induction. (C) Representative
fluorescence image of Tuj1-positive cells 7 days after neural induction of glioma with CHIR99021 (2 μM) and
forskolin (10 μM). (D) Representative image of Tuj1/DAPI staining at 7 days after treatment of mouse
embryonic fibroblasts with a combination of CHIR99021 (2 μM) and forskolin (10 μM). (E) Representative
image of Tuj1-positive cells 7 days after treatment of glioma with a variety of concentrations of CHIR99021
and forskolin. Scale bars represent 500 μm (A), 50 μm (B), 100 μm (C), 100 μm (D), and 100 μm (E).
https://doi.org/10.1371/journal.pone.0178881.g001
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Fig 2. Direct reprogramming of C6 glioma to neurons using two small molecules. (A) Representative fluorescence images of small
molecule-induced neurons (SMiNs) 35 days after neural induction with CHIR99021 (20 μM) and forskolin (100 μM). (B) Quantitative result of
Tuj1, MAP2, GFAP, PDGFR, and NG2 staining in SMiNs 35 days after neural induction. (C) Representative image of Tuj1- or MAP2-positive
SMiNs 35 days after neural induction with CHIR99021 (20 μM) and forskolin (100 μM). (D) Quantitative result of morphological complexity
of Tuj1-positive SMiNs 35 days after neural induction. (E) Representative band image of SSEA1 (a cancer stem cell marker) and C-Myc
(an oncogene marker) 35 days after neural induction with CHIR99021 (20 μM) and forskolin (100 μM). (F) Representative fluorescence
Neuronal direct conversion of glioma
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activator, especially CHIR99021 and forskolin, in the absence of neural transcription factors or
forced gene expression. To examine whether SMiNs differentiated from malignant glioma
demonstrated neuronal functionality, their electrophysiological properties were examined
by whole-cell patch clamp recording (Fig 2H). In voltage clamp mode, Na+ currents were
observed in SMiNs (Fig 2I, left). Action potential spikes appeared only in cells that produced
Na+ currents (Fig 2J, left). To confirm that the channels producing currents and spikes were
Na+ channels, the Na+ channel antagonist tetrodotoxin (TTX) was applied for 5–10 minutes.
TTX treatment completely blocked Na+ currents (Fig 2I, right) and action potential spikes (Fig
2J, right). We did not see any signal in undifferentiated glioma cultured in proliferation (Fig
2K) and neural differentiation (Fig 2L) media. Thus, electrophysiology results showed that the
characteristic of C6 glioma changed to that of functional neurons after combined treatment
with the two small molecules.
Growth suppression effect of a combination of CHIR99021 and forskolin
in vitro
Next, we examined the ability of small-molecule treatments to suppress the proliferation of
malignant glioma. The proliferation rate of C6 glioma cells is extremely fast, such that 100%
confluence was achieved within 7 days, despite initial seeding at a low density (2 × 103/cm2)
(Fig 3A). We aimed to determine the concentrations at which maximum inhibition of cell pro-
liferation could be achieved. We confirmed that a combination of 20 μM CHIR99021 and
100 μM forskolin significantly and powerfully inhibited C6 glioma cell proliferation (Fig 3B
and 3C). Of note, the combination of 20 μM CHIR99021 and 100 μM forskolin produced a
more powerful inhibition than any single-molecule treatment (Fig 3D and 3E). Next, we used
Ki-67, a proliferating cell marker, to identify proliferating cells in glioma and SMiN cultures.
While the most of control C6 glioma was Ki-67-positive, 11% Ki-67-positive cells were
observed in SMiN cultures (Fig 3F and 3G). In addition, this inhibition was also greater than
that of temozolomide (50 μM), a standard chemotherapeutic agent for treatment of brain
tumors (Fig 3H). These results indicate that the combination of CHIR99021 and forskolin con-
sistently and significantly suppressed the active proliferation of malignant glioma.
Growth suppression effect of a combination of CHIR99021 and forskolin
in patient-derived GBM
Next, we examined the ability of small-molecule treatments to suppress the proliferation of
patient-derived GBM. We confirmed that a combination of 10 μM CHIR99021 and 50 μM for-
skolin powerfully inhibited GBM proliferation (Fig 4A), and the growth inhibition effect was
also greater than that of temozolomide treatment (Fig 4B). The neuron-like morphology was
also observed in GBM treated with CHIR99021 and forskolin (Fig 4C). These results indicate
that the combination of CHIR99021 and forskolin induces growth inhibition in GBM.
images of SMiNs 7 days after neural induction with lithium carbonate (3 mM) and forskolin (100 μM). (G) Representative fluorescence
images of SMiNs 7 days after neural induction with CHIR99021 (2 μM) and dbcAMP (0.5 mM). (H) Representative images of patch-clamp
in SMiNs. (I) Representative traces of sodium current of SMiN 84 days after neural induction before (left) and after (right) 0.5μM TTX bath
application. (J) Representative traces of action potential spike of SMiN 84 days after neural induction before (left) and after (right) 0.5μM
TTX bath application. (K) Representative traces of sodium current (left) and action potential spike (right) of undifferentiated C6 glioma in
proliferation media. (L) Representative traces of sodium current (left) and action potential spike (right) of undifferentiated C6 glioma in
neural differentiation media without small molecules. Data are presented as the mean ± S.E.M. Scale bars represent 50 μm (A), 20 μm
(C), 100 μm (F), and 100 μm (G).
https://doi.org/10.1371/journal.pone.0178881.g002
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Gene expression profile of malignant glioma and SMiNs
We then investigated the gene expression profile regarding neural conversion and growth
inhibition in C6 glioma and SMiNs. In a microarray analysis, we confirmed that gene ontology
Fig 4. Growth suppression effect of a combination of CHIR99021 and forskolin in patient-derived GBM. (A)
Quantitative results of cell density 7 days after neural induction. (B) Quantitative results of cell density 7 days post-treatment.
C, CHIR99021 (10 μM); F, forskolin (50 μM); TMZ, temozolomide (50 μM). (C) Representative fluorescence image of
Tuj1-positive cells 7 days after neural induction with CHIR99021 and forskolin. * indicates p < 0.05. Data are presented as the
mean ± S.E.M. Scale bars represent 200 and 100 μm.
https://doi.org/10.1371/journal.pone.0178881.g004
Fig 3. Growth suppression effect of a combination of CHIR99021 and forskolin in C6 glioma. (A) The proliferation rate
of normal C6 glioma in neural induction media without small molecules. Cells were transferred to a new large dish at day 7. (B
and C) Quantitative results of cell density at day 7 after neural induction. (D) Quantitative results of cell density at day 7 after
neural induction. C, CHIR99021 (20 μM); F, forskolin (100 μM). (E) Quantitative results of cell density at days 7 and 14 days
after neural induction with CHIR99021 (20 μM) and forskolin (100 μM). (F and G) Representative image and percentages of
Ki67-positive cells in C6 glioma and SMiN cultures 35 days after neural induction with CHIR99021 (20 μM) and forskolin
(100 μM). (H) Quantitative results of cell density at 7 days post-treatment. C, CHIR99021 (20 μM); F, forskolin (100 μM); T,
temozolomide (50 μM). * indicates p < 0.05. Data are presented as the mean ± S.E.M. Scale bars represent 100 μm (F and
G).
https://doi.org/10.1371/journal.pone.0178881.g003
Neuronal direct conversion of glioma
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relating to cell differentiation, such as neuron development and projection, was up-regulated,
and that neuronal genes were highly expressed in SMiNs (Fig 5B, 5C and 5G). In contrast,
gene expression profiling and gene ontology relating to cell division and mitosis were
markedly up-regulated in C6 glioma (Fig 5B, 5D and 5G). In addition, gene expression profil-
ing and gene ontology relating to the extracellular matrix (ECM) and vessel development were
significantly down-regulated in SMiNs (Fig 5B and 5E–5G). These results validated that
CHIR99021 and forskolin induce both neural conversion and growth suppression on malig-
nant glioma.
Change of gene expression after treatment with CHIR99021 and
forskolin
We analyzed the change of gene expression relating to cell cycle, glioma development, cytokine-
cytokine receptor interaction, ECM-receptor interaction, cell adhesion molecule, PI3K-AKT,
Fig 5. Gene expression profile of a malignant glioma and SMiN. (A) Heat map of significant gene in C6 glioma and SMiNs. (B) Up- or
down-regulated gene ontology term in SMiNs. (C) Comparison of neuronal differentiation-related genes in C6 glioma and SMiNs. (D)
Comparison of cell cycle-related genes in C6 glioma and SMiNs. (E) Comparison of ECM-related genes in C6 glioma and SMiNs. (F)
Comparison of vessel development-related genes in C6 glioma and SMiNs. (G) Enriched gene list in C6 glioma and SMiNs.
https://doi.org/10.1371/journal.pone.0178881.g005
Neuronal direct conversion of glioma
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MAPK, and RAS signaling after treatment of small molecules (Table 1). Results indicate that the
combination treatment with CHIR99021 and forskolin inhibits the cell cycle and glioma develop-
ment, and lead to changes in cytokine-receptor interaction, ECM-receptor interaction and cell
adhesion molecule. It indicates that changes in the PI3K/AKT and RAS/MAPK signaling path-
ways were induced by the neural conversion after treatment with CHIR99021 and forskolin.
Anti-cancer effects of combined CHIR99021 and forskolin in a severe
IMSCT model
Next, we investigated whether the direct reprogramming technology based on the combina-
tion of small molecules can be applied to the treatment of malignant glioma. We verified the
anti-cancer effect of the combination treatment with both CHIR99021 and forskolin on a
severe IMSCT model. Interestingly, we confirmed that treatment with both CHIR99021 (12.5
mg/kg) and forskolin (10 mg/kg) markedly delayed the neurologic dysfunction in a severe
IMSCT model (Fig 6A). By 16 days after glioma transplantation, the tumor volume had signifi-
cantly decreased in the CHIR99021 and forskolin treated group (Fig 6B–6F).
Discussion
It has been reported that fibroblasts can be directly reprogrammed into neurons through the
forced expression of three pro-neuronal transcription factors [1]. This showed the possibility
that a malignant tumor can be converted to post-mitotic cells through direct reprogramming.
The direct conversion from a malignant tumor to benign cells is a potent therapeutic strategy
for removing tumor cells because terminally differentiated cells will die from apoptosis. In line
with this research, a previous study has shown that glioma can be converted to post-mitotic
neurons via the forced expression of neural reprogramming factors such as Ngn2 and Sox11
[13]. However, intrinsic limitations related to chromosomal gene insertion persist. The present
study is the first to show that glioma can be converted to neurons using small molecule repro-
gramming in the absence of neural transcription factors.
In a preliminary study, we investigated the neural conversion of glioma using a few small
molecule combinations that have been previously used for neural induction, such as a83-01,
Table 1. Change of gene expression relating to cell cycle, glioma development, cytokine-cytokine receptor interaction, ECM-receptor interaction,
cell adhesion molecule, PI3K-AKT, MAPK and RAS signaling pathway after treatment of small molecules.
Related Pathway Significantly down-regulated genes Significantly up-
regulated genes
Cell cycle CCNA2 (-4.56), CDC25B (-4.03), PLK1 (-5.04), MCM7 (-4.10), CCNB2 (-5.06), PTTG1 (-5.35),
CDC20 (-4.14), CDK4 (-2.94), CDK6 (-3.18)
NA
Glioma development PDGFRA (-16.57), PDGFRB (-5.39) NA
Cytokine-receptor
interaction
MET (-4.29), PDGFRB (-5.39), PDGFRA (-16.57), CSF1 (-5.49) NGFR (4.07)
ECM-receptor
interaction
RELN (-7.27), ITGA1 (-4.96), SPP1 (-22.95), COL1A1 (-4.76), COL6A1 (-6.58), LAMA2 (-5.50),
LAMA4 (-4.01), ITGA4 (-5.45), ITGB8 (-16.93)
NA
Cell adhesion
molecule
SDC3 (13.1), CD28 (-5.10), RT1-S3 (-5.39), PTPRM (-4.25), ITGA4 (-5.45), ITGB8 (-16.93) NRCAM (174.65)
PI3K/AKT signaling
pathway
LPAR1 (-6.25), MET (-4.29), PDGFRB (-5.39), RELN (-7.27), ITGA1 (-4.96), PDGFRA (-16.57),
SPP1 (-22.95), COL1A1 (-4.76), COL6A1 (-6.58), LAMA2 (-5.50), LAMA4 (-4.01), ITGA4 (-5.45),
PCK2 (-4.37), ITGB8 (-16.93), CSF1 (-5.49), PRKAA2 (-4.06), NF-κB (-2.76)
NGFR (4.07)
MAPK signaling
pathway
CDC25B (-4.03), PDGFRB (-5.39), NTRK2 (-7.48), PDGFRA (-16.57), RAPGEF2 (-4.26), RPS6KA5
(-4.57), MEF2C (-16.48)
NA
RAS signaling
pathway
ETS1 (-5.26), MET (-4.29), PDGFRB (-5.39), PDGFRA (-16.57), CSF1 (-5.49), KRAS (-2.52), NRAS
(-2.32)
NGFR (4.07)
https://doi.org/10.1371/journal.pone.0178881.t001
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dorsomorphin, CHIR99021, and forskolin. Seven days after combination treatment, CHIR
99021 and forskolin showed higher neural conversion compared to other combinations such
as A83-01/forskolin or A83-01/CHIR99021 and to any single treatment (Data not shown). In
addition, we used neuronal differentiation media containing pro-differentiation reagents
(such as N2, B27, BDNF, GDNF, and NT3) as a control. In the control group, we did not see
any neural conversion. Thus, we concluded that the combined treatment with CHIR99021 and
forskolin specifically induced neural conversion of glioma.
Neuronal direct reprogramming technology using a small molecule cocktail of 4–7 mole-
cules was reported in fibroblasts [17,18]. Nevertheless, neither other authors nor we could con-
firm that fibroblasts can be converted into Tuj1-positive neurons by combination treatment
with CHIR99021 and forskolin. In contrast, combination treatment with CHIR99021 and for-
skolin led to physiological and morphological changes in glioma. This result supports our
hypothesis that the fate decision of glioma is more flexible than that of fibroblasts.
In a microarray analysis, we confirmed that gene ontology relating to cell differentiation
was up-regulated in SMiNs. In contrast, gene expression profiling and gene ontology relating
to cell division and mitosis was markedly up-regulated in C6 glioma. These results are the first
to show the change of gene expression pattern relating to both neural conversion and growth
suppression after neural conversion via small molecules. We did not observe the expression of
any transcription factor implicated in neuronal conversion, such as Neurog2, after treatment
with CHIR99021 and forskolin for 5 weeks. A previous study has shown that combination
Fig 6. Anti-cancer effects of combined CHIR99021 and forskolin in a severe IMSCT model. (A) Neurologic function tests. (B)
Representative image of dissected spinal cord at 16 days post-transplantation with RFP-expressing C6 glioma. (C) Representative
optical imaging of dissected spinal cord at 16 days post-transplantation with RFP-expressing C6 glioma. (D) Representative image of
sagittal sectioned-spinal cord at 16 days post-transplantation with RFP-expressing C6 glioma. (E) Quantitative result of ROI at 16 days
post-transplantation with RFP-expressing C6 glioma. (F) Quantitative result of tumor area at 16 days post-transplantation with RFP-
expressing C6 glioma. C, CHIR99021 (12.5 mg/kg); F, forskolin (10 mg/kg). * indicates p < 0.05. Asterisk means a significant difference
to control. Data are presented as the mean ± S.E.M. Control (n = 11), CF (n = 7). Scale bars represent 1 cm (B) and 2 mm (D).
https://doi.org/10.1371/journal.pone.0178881.g006
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treatment with CHIR99021 and forskolin did not induce Neurog2 expression during neural
conversion from fibroblast to neuron [17, 18]. It is possible that a mechanism other than the
expression of transcription factors related to neural conversion is activated during C6 glioma
neural conversion.
Further, it is unknown which signaling pathway was involved in glioma–neural conversion
by forskolin and CHIR99021. In KEGG pathway analysis, we confirmed various changes in
cell cycle, molecular interaction/information, and signaling pathways after small-molecule
treatment.
In the cell cycle pathway, the MCM family, CDK 4/6, PLK1, and CDC20were markedly
down-regulated in SMiNs. The expression level of MCM, a useful marker of cancer prolifera-
tion, is increased in different cancer types [21]. The depletion of MCM7 inhibits glioblastoma
proliferation [22]. It has been reported that the use of CDK4/6 inhibitors can be applied for
glioblastoma treatment [23]. In addition, the serine/threonine-protein kinase PLK1, a trigger
of G2/M progression, is highly expressed in tumor cells [24]. These results indicate that the
combination treatment with CHIR99021 and forskolin inhibits the cell cycle.
Small-molecule treatment led to changes of the pathways relating to glioma development
and cytokine–receptor or ECM–receptor interaction. Especially, PDGFR was highly down-reg-
ulated in SMiNs. Thus, the downstream genes of PDGFR were also sequentially down-regu-
lated. It is known that epidermal growth factor receptor (EGFR), PDGFR, and Met (hepatocyte
growth factor receptor, HGFR) are expressed in glioma. Glioma expresses both the growth fac-
tor ligand and the receptor; hence, the autocrine and paracrine effects of growth factors may
regulate proliferation in glioma. It has been reported that glioma growth, invasion, and angio-
genesis signals are related to ECM components such as collagen, laminin, and integrin, and to
receptor tyrosine kinase (RTK) genes such as EGFR, PDGFR, IGF1R, and Met [25]. Given the
major role of ECM and RTK in glioma invasion and angiogenesis, down-regulation of genes
relating to ECM-receptors or cytokine receptors interaction by CHIR99021 and forskolin may
lead to the suppression of angiogenesis and glioma invasion in vivo.
Small-molecule treatment led to changes of RTK/PI3K/AKT and RAS/RAF/MAPK signal-
ing pathways on glioma. The activated PDGF receptor triggers both the PI3K/AKT and
RAS/RAF/ERK1/2 signaling pathways [25,26]. In the PI3K pathway, the PDGF expression
increases the expression of NF-κB regulating cell proliferation and survival [25]. In addition,
the PI3K/AKT pathway is implicated in glioma invasion [23]. It has been reported that tran-
scription factors c-jun, c-myc, and c-fos are involved in cell proliferation. KEGG pathway
analysis showed that these genes are involved in the MAPK pathway, and three transcription
factors were down-regulated in SMiNs. These results indicate that the combination treatment
with CHIR99021 and forskolin induced the neural conversion of glioma, and led to changes in
the RTK/PI3K/AKT and RAS/RAF/MAPK signaling pathways involving cell growth and
proliferation.
In a growth inhibition experiment in which small molecules were added to C6 glioma or
GBM, GBM was more resistant to forskolin compared to C6 glioma. It is possible that some
factors, such as cell type-specific differences or heterogeneity, may affect the results. Moreover,
a previous study has shown that the drug response is different for each single clone of GBM
[27]; Nevertheless, the combination of CHIR99021 and forskolin showed stronger growth
inhibition effect compared to single treatment with either CHIR99021 or forskolin. However,
the response to CHIR99021 and forskolin should be tested in various GBM clones. In the
future, we plan to confirm our findings on GBM in vivo.
Collectively, combination treatment with small molecules led to various changes involving
gene expression, cell-specific marker expression, signal transduction pathways, and phy-
siological and morphological changes in glioma. These findings demonstrated that direct
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reprogramming technology based on small molecules can be applied to suppress the prolifera-
tion of malignant glioma. We suggest that a combination molecule comprising a GSK3 inhibi-
tor and cAMP inducer would be a candidate molecule for the next-generation of anticancer
drug, and that reprogramming technology is a potential therapeutic strategy that could poten-
tially replace the therapeutic paradigm of the traditional treatment of malignant glioma.
Supporting information
S1 Checklist. Completed “The ARRIVE Guidelines Checklist” for reporting animal data in
this manuscript.
(DOCX)
Acknowledgments
This study was supported by a National Research Foundation of Korea Grant, funded by the
Korean Government (NRF-2015R1A6A3A01018883). This research was supported by Basic
Science Research Program through the National Research Foundation of Korea (NRF) funded
by the Ministry of Education (2015R1D1A1A02059821 and 2016R1D1A1A02937027)
Author Contributions
Conceptualization: JO YH.
Data curation: JO.
Formal analysis: JO YK LC GEC EC S-GK.
Funding acquisition: YH.
Investigation: JO YK LC JBK GEC EC.
Methodology: JO.
Project administration: JO YH.
Resources: JO YK LC S-GK.
Software: JO YK LC.
Supervision: YH.
Validation: JO YK LC.
Visualization: JO YH.
Writing – original draft: JO YH.
Writing – review & editing: JO YH.
References
1. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Su¨dhof TC, Wernig M. Direct conversion of fibro-
blasts to functional neurons by defined factors. Nature. 2010; 463: 1035–1041 https://doi.org/10.1038/
nature08797 PMID: 20107439
2. Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, et al. Induction of human neuro-
nal cells by defined transcription factors. Nature. 2011; 476: 220–223. https://doi.org/10.1038/
nature10202 PMID: 21617644
Neuronal direct conversion of glioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178881 November 21, 2017 13 / 15
3. Caiazzo M, Dell’Anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D, et al. Direct generation of
functional dopaminergic neurons from mouse and human fibroblasts. Nature. 2011; 476: 224–227.
https://doi.org/10.1038/nature10284 PMID: 21725324
4. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y, et al. MicroRNA-mediated conversion of
human fibroblasts to neurons. Nature. 2011; 476: 228–231. https://doi.org/10.1038/nature10323 PMID:
21753754
5. Karow M, Sanchez R, Schichor C, Masserdotti G, Ortega F, Heinrich C, et al. Reprogramming of peri-
cyte-derived cells of the adult human brain into induced neuronal cells. Cell Stem Cell. 2012; 11: 471–
476. https://doi.org/10.1016/j.stem.2012.07.007 PMID: 23040476
6. Ring KL, Tong LM, Balestra ME, Javier R, Andrews-Zwilling Y, Li G, et al. Direct reprogramming of
mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell.
2012; 11: 100–109. https://doi.org/10.1016/j.stem.2012.05.018 PMID: 22683203
7. Han DW, Tapia N, Hermann A, Hemmer K, Hoing S, Arauzo-Bravo MJ, et al. Direct reprogramming of
fibroblasts into neural stem cells by defined factors. Cell Stem Cell. 2012; 10: 465–472. https://doi.org/
10.1016/j.stem.2012.02.021 PMID: 22445517
8. Yang N, Zuchero JB, Ahlenius H, Marro S, Ng YH, Vierbuchen T, et al. Generation of oligodendroglial
cells by direct lineage conversion. Nat Biotechnol. 2013; 31: 434–439. https://doi.org/10.1038/nbt.2564
PMID: 23584610
9. Najm FJ, Lager AM, Zaremba A, Wyatt K, Caprariello AV, Factor DC, et al. Transcription factor-medi-
ated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nat
Biotechnol. 2013; 31: 426–433. https://doi.org/10.1038/nbt.2561 PMID: 23584611
10. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem
cells. Cell. 2012; 149: 36–47. https://doi.org/10.1016/j.cell.2012.03.009 PMID: 22464322
11. Sukhdeo K, Hambardzumyan D, Rich JN. Glioma development: where did it all go wrong? Cell. 2011;
146: 187–188. https://doi.org/10.1016/j.cell.2011.06.047 PMID: 21784240
12. Guichet PO, Bieche I, Teigell M, Serguera C, Rothhut B, Rigau V, et al. Cell death and neuronal differ-
entiation of glioblastoma stem-like cells induced by neurogenic transcription factors. Glia. 2013; 61:
225–239 https://doi.org/10.1002/glia.22429 PMID: 23047160
13. Su Z, Zang T, Liu M, Wang L, Niu W, Zhang C. Reprogramming the fate of human glioma cells to
impede brain tumor development. Cell death & disease. 2014; 5: e1463
14. Ladewig J, Mertens J, Kesavan J, Doerr J, Poppe D, Glaue F, et al. Small molecules enable highly effi-
cient neuronal conversion of human fibroblasts. Nat Methods. 2012; 9: 575–578. https://doi.org/10.
1038/nmeth.1972 PMID: 22484851
15. Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G. In Vivo direct reprogramming of reactive glial cells
into functional neurons after brain injury and in an Alzheimer’s disease model. Cell Stem Cell. 2014; 14:
188–202. https://doi.org/10.1016/j.stem.2013.12.001 PMID: 24360883
16. Liu Y, Miao Q, Yuan J, Han S, Zhang P, Li S, et al. Ascl1 Converts Dorsal Midbrain Astrocytes into
Functional Neurons In Vivo. J Neurosci. 2015; 35: 9336–9355. https://doi.org/10.1523/JNEUROSCI.
3975-14.2015 PMID: 26109658
17. Li X, Zuo X, Jing J, Ma Y, Wang J, Liu D, et al. Small-Molecule-Driven Direct Reprogramming of Mouse
Fibroblasts into Functional Neurons. Cell Stem Cell. 2015; 17: 195–203. https://doi.org/10.1016/j.stem.
2015.06.003 PMID: 26253201
18. Hu W, Qiu B, Guan W, Wang Q, Wang M, Li W, et al. Direct Conversion of Normal and Alzheimer’s Dis-
ease Human Fibroblasts into Neuronal Cells by Small Molecules. Cell Stem Cell. 2015; 17: 204–212.
https://doi.org/10.1016/j.stem.2015.07.006 PMID: 26253202
19. Gwak S-J, An SS, Yang MS, Joe E, Kim D-H, Kim KN, et al. Effect of combined bevacizumab and temo-
zolomide treatment on intramedullary spinal cord tumor. Spine. 2014; 39: E65–E73 https://doi.org/10.
1097/BRS.0000000000000070 PMID: 24158177
20. Kim EH LJ, Oh Y, Koh I, Shim JK, Park J, Choi J, Yun M, Jeon JY, Huh YM, Chang JH, Kim SH, Kim
KS, Cheong JH, Kim P, Kang SG. Inhibition of glioblastoma tumorspheres by combined treatment with
2-deoxyglucose and metformin. Neuro Oncology. 2016; 0: 1–10. Neuro-Oncology xx(xx), 1–10, 2016
https://doi.org/10.1093/neuonc/now174 PMID: 27571886
21. Nowinska K CM, Piotrowska A, Pula B, Pastuszewski W, Krecicki T, Podhorska-Okołow M, Zabel M,
Dziegiel P. Correlation between levels of expression of minichromosome maintenance proteins, Ki-67
proliferation antigen and metallothionein I/II in laryngeal squamous cell cancer. Int J Oncol. 2016; 48:
635–645 https://doi.org/10.3892/ijo.2015.3273 PMID: 26648405
22. Erkan TSb EP, Lewandrowski G, Tannous B, Madlener S, Czech T, Saydam N and Saydam O. Deple-
tion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo.
Oncogene. 2014; 33: 4778–4785. https://doi.org/10.1038/onc.2013.423 PMID: 24166506
Neuronal direct conversion of glioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178881 November 21, 2017 14 / 15
23. Schroder LB, McDonald KL. CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a
Future? Front Oncol. 2015; 5: 259. https://doi.org/10.3389/fonc.2015.00259 PMID: 26649278
24. Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, et al. Polo-like kinase 1 inhibition kills
glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in
mice. Stem Cells. 2012; 30: 1064–1075. https://doi.org/10.1002/stem.1081 PMID: 22415968
25. Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, et al. Aberrant signaling pathways in gli-
oma. Cancers (Basel). 2011; 3: 3242–3278. https://doi.org/10.3390/cancers3033242 PMID: 24212955
26. Carrasco-Garcia E, Saceda M, Martinez-Lacaci I. Role of receptor tyrosine kinases and their ligands in
glioblastoma. Cells. 2014; 3: 199–235. https://doi.org/10.3390/cells3020199 PMID: 24709958
27. Mona Meyer JR, Xiaoyang Lan, Renee Head, Xueming Zhu, Michelle Kushida. Single cell-derived
clonal analysis of human glioblastoma links functional and genomic heterogeneity. PNAS. 2015; 112:
851–856 https://doi.org/10.1073/pnas.1320611111 PMID: 25561528
Neuronal direct conversion of glioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178881 November 21, 2017 15 / 15
